1 |
KCDC. Guidelines for viral Hepatitic C prevention and control [Internet]. Cheonwon: Korea centers for disease control and prevention; 2016 [cited 2018 July 6]. Available from: http://www.cdc.go.kr/CDC/main.jsp.
|
2 |
Choo QL, Weiner AJ, Overby LR, Kuo G, Houghton M, Bradley DW. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br med Bull. 1990;46:423-441.
DOI
|
3 |
Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244: 359-362.
DOI
|
4 |
Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science. 1989;244: 362-364.
DOI
|
5 |
Tanaka E, Kiyosawa K, Nakatsuji Y, Inoue Y, Miyamura T, Chiba J, et al. Clinical significance of antibodies to nonstructural and core proteins of hepatitis C virus in post transfusion hepatitis patients during long-term follow-up. J med Virol. 1993;39:318-324.
DOI
|
6 |
Zeuzem S, Ruster B, Roth WK. Clinical evaluation of a new polymerase chain reaction assay (Amplicor HCV) for detection of hepatitis C virus. J Gasteroenterol. 1994;32:342-347.
|
7 |
Inchauspe G, Zebedee S, Lee DH, Sugitani M, Nasoff M, Prince AM. Genomic structure of the human protype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc Natl Acad Sci. 1991;88:10292-10296.
DOI
|
8 |
Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci. 1994;39:977-982.
DOI
|
9 |
McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994;32:884-892.
|
10 |
Okamoto H, Okada S, Sugiyama Y, Kurai K, Iizuka H, Machida A, et al. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolates for conserved and divergent regions. J Gen Virol. 1991;72:2679-2704.
DOI
|
11 |
Yoshioka K, Kakumu S. Predicting factors for the response to interferon therapy against hepatitis C virus infection: HCV genotyping. Rinsho Byori. 1994;42:1010-1014.
|
12 |
Verbaan H, Widell A, Lindgren S, Lindmark B, Nordenfelt E, Eriksson S. Hepatitis C in chronic liver disease: an epidemiological study based on 566 consecutive patients undergoing liver biopsy during a 10-year period. J Int Med. 1992;232:33-42.
DOI
|
13 |
Simmonds P, Zhang LQ, Watson HG, Rebus S, Ferguson ED, Balfe P, et al. Hepatitis C quantification and sequencing in blood products, haemophiliacs, and drug users. Lancet. 1990;336:1469-1472.
DOI
|
14 |
van der Poel CL, Reesink HW, Schaasberg W, Leentvaar-Kuypers A, Bakker E, Exel-Oehlers PJ, et al. Infective of blood seropositive for hepatitis C virus antibodies. Lancet. 1990; 335:558-560.
DOI
|
15 |
Seong MH, Kil H, Kim YS, Bae SH, Lee YJ, Lee HC, Kang BH, Jeong SH. Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J Med Virol. 2013;85:1724-1733.
DOI
|